TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

Contributed by: Business Wire

Logo

Tags

Science

Other Science

Biotechnology

Research

Health

FDA

Infectious Diseases

Other Health

TriLink BioTechnologies

More Like This

TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)

TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production

TriLink BioTechnologies® Partners with Avantor® to Expand Nucleic Acid Solutions in Europe

TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase

Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

PR Newswire associated0

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

PR Newswire associated0

LenioBio Collaborates with ReciBioPharm to Scale Up ALiCE® Technology and Expedite Vaccine Production